New Advances in Cholangiocarcinoma and Dravet Syndrome Treatment Highlighted in The New England Journal of Medicine

Recent publications in The New England Journal of Medicine (NEJM) showcase promising developments in the treatment of two distinct conditions: intrahepatic cholangiocarcinoma, a rare bile duct cancer, and Dravet syndrome, a severe genetic neurodevelopmental disorder. These findings, released on March 5, 2026, suggest potential shifts in standard care for both diseases.

Breakthroughs in Cholangiocarcinoma Treatment

A phase II clinical trial published in NEJM details the potential benefits of neoadjuvant therapy – treatment administered before surgery – for patients with resectable high-risk intrahepatic cholangiocarcinoma. Researchers found that a combination of gemcitabine, oxaliplatin, and lenvatinib (GOLP) significantly improved pathologic outcomes compared to the standard gemcitabine plus oxaliplatin (GEP) regimen.

Intrahepatic cholangiocarcinoma, representing 30% to 50% of all cholangiocarcinoma cases, often presents at a late stage, making effective treatment challenging. While surgical resection offers the best chance for long-term survival, recurrence rates remain high, particularly in patients with high-risk features. The GOLP regimen demonstrated a statistically significant improvement in pathologic complete response (pCR) rates, with 24.2% of patients achieving pCR compared to 6% with GEP. This suggests that GOLP may shrink tumors and eliminate microscopic disease before surgery, potentially improving long-term outcomes. [Source: Archyde]

Potential Disease Modification in Dravet Syndrome

In a separate publication, NEJM featured data from studies of zorevunersen, an investigational medicine targeting the underlying cause of Dravet syndrome. Results from Phase 1/2a trials and ongoing open-label extension (OLE) studies indicate the potential for disease modification in individuals living with this rare and devastating genetic neurodevelopmental disease. [Source: Pharmiweb]

Dravet syndrome is characterized by severe and recurrent seizures and a plateauing of neurodevelopment around the age of two. Currently, there are no approved disease-modifying medicines for this condition. Data suggest that zorevunersen, used in conjunction with standard anti-seizure medications, led to substantial and durable reductions in seizures and improvements in cognition and behavior, observed both during the initial treatment period and sustained over three additional years in the OLEs.

Looking Ahead

The publications in the March 5, 2026, issue of The New England Journal of Medicine represent significant steps forward in the treatment of both intrahepatic cholangiocarcinoma and Dravet syndrome. Further research and clinical trials will be crucial to confirm these findings and establish new standards of care for these challenging conditions. The NEJM continues to be a leading source for cutting-edge medical research and advancements. [Source: NEJM Image Challenge] [Source: NEJM Issues 2026]